GlobeNewswire: Actelion Pharmaceuticals Ltd Contains the last 10 of 54 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T06:52:30ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/10/31/1160492/0/de/Cancellation-of-publicly-held-Actelion-shares-and-delisting-from-SIX-Swiss-Exchange-as-of-November-7-2017.html?f=22&fvtc=4&fvtv=30119Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 20172017-10-31T06:02:23Z<![CDATA[ALLSCHWIL/BASEL, SWITZERLAND - October 31, 2017 - By decision dated October 25, 2017, the Cantonal Court of the Canton of Basel-Landschaft cancelled all publicly held registered shares of Actelion Ltd (Actelion) with a nominal value of CHF 0.50 each (the Actelion Shares) based on article 137 of the Federal Act on Financial Market Infrastructures and Market Conduct in Securities and Derivatives Trading (Financial Market Infrastructure Act).]]>https://www.globenewswire.com/news-release/2017/10/31/1160492/0/en/Cancellation-of-publicly-held-Actelion-shares-and-delisting-from-SIX-Swiss-Exchange-as-of-November-7-2017.html?f=22&fvtc=4&fvtv=30119Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 20172017-10-31T06:02:23Z<![CDATA[ALLSCHWIL/BASEL, SWITZERLAND - October 31, 2017 - By decision dated October 25, 2017, the Cantonal Court of the Canton of Basel-Landschaft cancelled all publicly held registered shares of Actelion Ltd (Actelion) with a nominal value of CHF 0.50 each (the Actelion Shares) based on article 137 of the Federal Act on Financial Market Infrastructures and Market Conduct in Securities and Derivatives Trading (Financial Market Infrastructure Act).]]>https://www.globenewswire.com/news-release/2017/06/30/1035286/0/en/Befreiung-von-Publizit%C3%A4tspflichten-zur-Aufrechterhaltung-der-Kotierung.html?f=22&fvtc=4&fvtv=30119Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung2017-06-30T05:02:13Z<![CDATA[ALLSCHWIL/BASEL, SCHWEIZ - 30. Juni 2017 - Am 16. Februar 2017 hat Janssen Holding GmbH, eine Tochtergesellschaft von Johnson & Johnson (NYSE:JNJ), den Angebotsprospekt zum öffentlichen Kaufangebot für alle sich im Publikum befindenden Namenaktien der Actelion Ltd (SIX:ATLN) publiziert. Das öffentliche Kaufangebot wurde am 16. Juni 2017 vollzogen.]]>https://www.globenewswire.com/news-release/2017/06/30/1035286/0/de/Befreiung-von-Publizit%C3%A4tspflichten-zur-Aufrechterhaltung-der-Kotierung.html?f=22&fvtc=4&fvtv=30119Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung2017-06-30T05:02:13Z<![CDATA[ALLSCHWIL/BASEL, SCHWEIZ - 30. Juni 2017 - Am 16. Februar 2017 hat Janssen Holding GmbH, eine Tochtergesellschaft von Johnson & Johnson (NYSE:JNJ), den Angebotsprospekt zum öffentlichen Kaufangebot für alle sich im Publikum befindenden Namenaktien der Actelion Ltd (SIX:ATLN) publiziert. Das öffentliche Kaufangebot wurde am 16. Juni 2017 vollzogen.]]>https://www.globenewswire.com/news-release/2017/06/16/1025159/0/de/Johnson-Johnson-Completes-Acquisition-of-Actelion.html?f=22&fvtc=4&fvtv=30119Johnson & Johnson Completes Acquisition of Actelion2017-06-16T05:01:23Z<![CDATA[ALLSCHWIL/BASEL, SWITZERLAND - 16 June 2017 - Actelion Ltd (SIX: ATLN) today announced the completion of the acquisition of Actelion Ltd by Johnson & Johnson for a total purchase price of approximately $30 billion in cash. The acquisition was completed through an all-cash public tender offer by Johnson & Johnson's Swiss subsidiary, Janssen Holding GmbH, to acquire all publicly held shares of Actelion Ltd for $280 per share, payable in U.S. dollars. Actelion will now become part of the Janssen Pharmaceutical Companies of Johnson & Johnson.]]>https://www.globenewswire.com/news-release/2017/06/16/1025159/0/en/Johnson-Johnson-Completes-Acquisition-of-Actelion.html?f=22&fvtc=4&fvtv=30119Johnson & Johnson Completes Acquisition of Actelion2017-06-16T05:01:23Z<![CDATA[ALLSCHWIL/BASEL, SWITZERLAND - 16 June 2017 - Actelion Ltd (SIX: ATLN) today announced the completion of the acquisition of Actelion Ltd by Johnson & Johnson for a total purchase price of approximately $30 billion in cash. The acquisition was completed through an all-cash public tender offer by Johnson & Johnson's Swiss subsidiary, Janssen Holding GmbH, to acquire all publicly held shares of Actelion Ltd for $280 per share, payable in U.S. dollars. Actelion will now become part of the Janssen Pharmaceutical Companies of Johnson & Johnson.]]>https://www.globenewswire.com/news-release/2017/06/14/1018834/0/de/Actelion-announces-changes-to-its-executive-team-upon-completion-of-the-transaction-with-Johnson-Johnson.html?f=22&fvtc=4&fvtv=30119Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson2017-06-14T15:36:04Z<![CDATA[ALLSCHWIL/BASEL, SWITZERLAND - 14 June 2017 - Actelion Ltd (SIX: ATLN) today announced changes to its executive team that will take effect upon the settlement of the public tender offer by Johnson & Johnson's Swiss subsidiary, Janssen Holding GmbH, for all publicly held shares of Actelion which is expected to occur on 16 June 2017 (Settlement).]]>https://www.globenewswire.com/news-release/2017/06/14/1018834/0/en/Actelion-announces-changes-to-its-executive-team-upon-completion-of-the-transaction-with-Johnson-Johnson.html?f=22&fvtc=4&fvtv=30119Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson2017-06-14T15:36:04Z<![CDATA[ALLSCHWIL/BASEL, SWITZERLAND - 14 June 2017 - Actelion Ltd (SIX: ATLN) today announced changes to its executive team that will take effect upon the settlement of the public tender offer by Johnson & Johnson's Swiss subsidiary, Janssen Holding GmbH, for all publicly held shares of Actelion which is expected to occur on 16 June 2017 (Settlement).]]>https://www.globenewswire.com/news-release/2017/06/09/1012160/0/en/Publication-of-Idorsia-s-prospectus-relating-to-the-listing-of-Idorsia-Ltd-on-SIX-Swiss-Exchange.html?f=22&fvtc=4&fvtv=30119Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange 2017-06-09T15:46:26Z<![CDATA[ALLSCHWIL/BASEL, SWITZERLAND - 09 June 2017 - Actelion Ltd (SIX:ATLN) today published the listing prospectus relating to the listing of Idorsia shares on SIX Swiss Exchange. With the tender offer for all publicly held shares of Actelion Ltd by Janssen Holding GmbH, a Swiss subsidiary of Johnson & Johnson (J&J) for Actelion on track for completion, it is expected that the settlement of the tender offer by J&J will take place on 16 June 2017. The demerger distribution, approved by the General Meeting of Actelion Shareholders held on 5 April 2017, will take place concurrently, whereby all Actelion shareholders (whether they tendered their shares or not) will receive one Idorsia share per each Actelion share held on 13 June 2017. It is expected that Idorsia shares will be listed and commence trading on SIX Swiss Exchange on 16 June 2017.]]>https://www.globenewswire.com/news-release/2017/06/09/1012160/0/de/Publication-of-Idorsia-s-prospectus-relating-to-the-listing-of-Idorsia-Ltd-on-SIX-Swiss-Exchange.html?f=22&fvtc=4&fvtv=30119Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange 2017-06-09T15:46:26Z<![CDATA[ALLSCHWIL/BASEL, SWITZERLAND - 09 June 2017 - Actelion Ltd (SIX:ATLN) today published the listing prospectus relating to the listing of Idorsia shares on SIX Swiss Exchange. With the tender offer for all publicly held shares of Actelion Ltd by Janssen Holding GmbH, a Swiss subsidiary of Johnson & Johnson (J&J) for Actelion on track for completion, it is expected that the settlement of the tender offer by J&J will take place on 16 June 2017. The demerger distribution, approved by the General Meeting of Actelion Shareholders held on 5 April 2017, will take place concurrently, whereby all Actelion shareholders (whether they tendered their shares or not) will receive one Idorsia share per each Actelion share held on 13 June 2017. It is expected that Idorsia shares will be listed and commence trading on SIX Swiss Exchange on 16 June 2017.]]>